The expert panel of the U.S. Department of Health and Human Services recommends starting antiretroviral therapy (ART) as soon as possible after HIV is diagnosed, regardless of CD4 count. Most people starting HIV treatment for the first time (treatment-naïve) should take one of the following: Biktarvy, Dovato, Triumeq, or Tivicay plus Descovy or Truvada. Go to hivinfo.nih.gov for more information.
The following are available as co-formulated drugs
(Not a complete list)
Atripla: EFV/FTC/TDF Biktarvy: BIC/FTC/TAF Cimduo or Temixys: 3TC/TDF Complera: RPV/FTC/TDF Delstrigo: DOR/3TC/TDF Descovy: FTC/TAF Dovato: DTG/3TC Epzicom: ABC/3TC Evotaz: ATV/c Genvoya: EVG/c/FTC/TAF Odefsey: RPV/FTC/TAF Prezcobix: DRV/c Stribild: EVG/c/FTC/TDF Symfi: EFV 600 mg/3TC/TDF Symfi Lo: EFV 400 mg/3TC/TDF Symtuza: DRV/c/FTC/TAF Triumeq: DTG/ABC/3TC Truvada: FTC/TDF
Rating of recommendations
A: Strong B: Moderate C: Optional
Rating of evidence
- Data from randomized controlled trials.
- Data from well-designed non-randomized trials, observational cohort studies with long-term clinical outcomes, relative bioavailability/bioequivalence studies, or regimen comparisons from randomized switch studies.
- Expert opinion.